{"id":71388,"date":"2026-05-20T08:30:59","date_gmt":"2026-05-20T08:30:59","guid":{"rendered":"https:\/\/medsbase.com\/ara-290\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"ara-290","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/ara-290\/","title":{"rendered":"ARA-290 (Cibinetida)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es ARA-290?<\/h3>\n<p style=\"margin: 0;\"><strong>ARA-290<\/strong> (cibinetide; Helix B Surface Peptide, HBSP) is an 11-amino-acid synthetic peptide derived from helix B of erythropoietin (EPO). Designed by Brines &amp; Cerami to dissociate EPO&#8217;s cytoprotective effects from its erythropoietic effects, ARA-290 binds the innate repair receptor (IRR) \u2014 a heterocomplex of the EPO receptor and the beta-common receptor (CD131) \u2014 and triggers anti-inflammatory, anti-apoptotic, and tissue-repair signalling without elevating red-cell mass. Developed by Araim Pharmaceuticals; orphan-designated for sarcoidosis-associated small-fiber neuropathy. Supplied in 10 mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1208243-50-8 (cibinetide)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00e9ptido sint\u00e9tico de 11 amino\u00e1cidos no eritropoy\u00e9tico derivado de la h\u00e9lice B de la eritropoyetina humana (Helix B Surface Peptide, HBSP); agonista del receptor innato de reparaci\u00f3n (IRR); c\u00f3digos de desarrollo ARA-290 \/ cibinetide (Araim Pharmaceuticals)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>51<\/sub>H<sub>84<\/sub>N<sub>16<\/sub>O<sub>21<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~1,257.4 Da<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">H-pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH (pyrEEQLERALNSS) \u2014 secuencia lineal de 11 residuos correspondiente a la cara expuesta al agua de la h\u00e9lice B de la eritropoyetina humana. La glutamina N-terminal se cicliza espont\u00e1neamente a piroglutamato (consistente con el peso molecular publicado de 1,257.4 Da). El extremo C-terminal es un \u00e1cido libre; sin puente disulfuro, sin acilaci\u00f3n de \u00e1cidos grasos, sin PEGilaci\u00f3n.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado (blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar en ~14\u201328 d\u00edas. Proteger de la luz. Evitar ciclos repetidos de congelaci\u00f3n-descongelaci\u00f3n de la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril. Altamente soluble; el 11-mero sin modificar se disuelve r\u00e1pidamente con un suave agitado.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es ARA-290?<\/h2>\n<p><strong>ARA-290<\/strong> (cibinetide) es un p\u00e9ptido sint\u00e9tico lineal de 11 amino\u00e1cidos correspondiente a la cara expuesta al agua de la h\u00e9lice B de la eritropoyetina humana (EPO) \u2014una regi\u00f3n de la mol\u00e9cula de EPO que no est\u00e1 involucrada en la uni\u00f3n al receptor cl\u00e1sico de EPO homodim\u00e9rico (EPOR<sub>2<\/sub>) que impulsa la producci\u00f3n de gl\u00f3bulos rojos. ARA-290 fue dise\u00f1ado racionalmente por Michael Brines y Anthony Cerami en Araim Pharmaceuticals para disociar dos actividades farmacol\u00f3gicamente distintas de la EPO que hist\u00f3ricamente hab\u00edan estado entrelazadas en una sola mol\u00e9cula: <strong>eritropoyesis<\/strong> (el efecto de aumento del hematocrito que limita el uso de la EPO como agente protector tisular debido al riesgo tromboemb\u00f3lico) y <strong>protecci\u00f3n tisular<\/strong> (the anti-inflammatory, anti-apoptotic, and repair-promoting effects mediated by a distinct heteromeric receptor). By restricting the peptide sequence to the helix-B surface face, ARA-290 retains affinity for the <strong>receptor de reparaci\u00f3n innata (IRR)<\/strong> \u2014 un heterocomplejo compuesto por la subunidad del receptor de EPO (EPOR) y el receptor beta com\u00fan (\u03b2cR, CD131; la subunidad de se\u00f1alizaci\u00f3n compartida de los receptores de GM-CSF, IL-3 e IL-5) \u2014 mientras que elimina la uni\u00f3n al homod\u00edmero de EPOR<sub>2<\/sub> homodimer responsible for erythropoiesis. The net effect is a peptide that produces EPO&#8217;s cytoprotective, anti-inflammatory, and neuroprotective effects in tissue without elevating hematocrit or carrying the thromboembolic and hypertensive risks that constrain therapeutic EPO use. ARA-290 has a short plasma half-life of approximately 2 minutes \u2014 the molecule is rapidly cleared \u2014 but the biological effect persists for 24\u201372 hours through downstream activation of cytoprotective signalling cascades (JAK2\/STAT3, PI3K\/Akt, anti-apoptotic Bcl-2 family upregulation). This pharmacokinetic profile is characteristic of receptor-trigger peptides where the duration of effect is driven by signal-cascade kinetics rather than by sustained plasma levels. ARA-290 has held <strong>la designaci\u00f3n de medicamento hu\u00e9rfano<\/strong> in the United States and the European Union for sarcoidosis-associated small-fiber neuropathy, and has been evaluated in multiple Phase 2 clinical trials in diabetic neuropathy and sarcoidosis-associated neuropathic pain. <\/p>\n<h2>Mecanismo de acci\u00f3n \u2014 Agonismo del receptor de reparaci\u00f3n innata sin eritropoyesis<\/h2>\n<p>What makes ARA-290 pharmacologically distinctive is that it activates the cytoprotective limb of erythropoietin signalling while bypassing the erythropoietic limb. Three mechanisms are documented in published studies:<\/p>\n<ul>\n<li><strong>Agonismo del receptor de reparaci\u00f3n innata (IRR) \u2014 heterocomplejo EPOR + \u03b2cR \/ CD131<\/strong> \u2014 En condiciones inflamatorias o de lesi\u00f3n hip\u00f3xica, las c\u00e9lulas tisulares aumentan la expresi\u00f3n del receptor beta com\u00fan (\u03b2cR, CD131) y ensamblan un heterocomplejo con el receptor de EPO (EPOR). Este heterocomplejo IRR es el objetivo molecular de ARA-290. La uni\u00f3n desencadena la fosforilaci\u00f3n de JAK2 y la activaci\u00f3n descendente de STAT3 \/ STAT5 \/ PI3K-Akt, lo que lleva a la regulaci\u00f3n al alza de prote\u00ednas anti-apopt\u00f3ticas (Bcl-2, Bcl-xL), la supresi\u00f3n de la producci\u00f3n de citocinas proinflamatorias (TNF-\u03b1, IL-1\u03b2, IL-6) y el reclutamiento de programas de reparaci\u00f3n tisular. Dado que el IRR se regula al alza localmente en los sitios de lesi\u00f3n o inflamaci\u00f3n en lugar de expresarse constitutivamente, ARA-290 act\u00faa como un agonista restringido por el contexto que activa la se\u00f1alizaci\u00f3n de reparaci\u00f3n espec\u00edficamente donde se necesita.<\/li>\n<li><strong>Sin uni\u00f3n al EPOR homodim\u00e9rico<sub>2<\/sub> \u2014 sin eritropoyesis<\/strong> \u2014 El receptor eritropoy\u00e9tico cl\u00e1sico en los progenitores eritroides de la m\u00e9dula \u00f3sea es un homod\u00edmero de dos subunidades EPOR sin participaci\u00f3n de CD131. ARA-290 tiene una afinidad insignificante por este homod\u00edmero, raz\u00f3n por la cual la dosificaci\u00f3n repetida en ensayos cl\u00ednicos no produce cambios detectables en la hemoglobina, el hematocrito o el recuento de reticulocitos. Esta es la caracter\u00edstica de dise\u00f1o central que distingue a ARA-290 de la EPO de longitud completa y de los an\u00e1logos de EPO dise\u00f1ados anteriormente (darbepoetina, CERA) que conservaban la actividad eritropoy\u00e9tica.<\/li>\n<li><strong>Efectos antiinflamatorios y de reparaci\u00f3n tisular descendentes<\/strong> \u2014 In preclinical and clinical studies, ARA-290 reduces pro-inflammatory cytokine production by activated macrophages, lowers neuropathic-pain scores in small-fiber neuropathy models, accelerates corneal wound healing, reduces ischemia-reperfusion injury in renal and cardiac models, and improves glycemic control in type 2 diabetes preclinical models. The breadth of effect reflects the broad tissue distribution of the IRR under inflammatory conditions rather than a tissue-specific mechanism.<\/li>\n<\/ul>\n<p>The short plasma half-life (~2 minutes) combined with sustained biological effect (24\u201372 hours) means ARA-290 protocols typically use daily or every-other-day dosing despite the rapid molecular clearance \u2014 the pharmacodynamic duration is set by the downstream signalling cascade, not by plasma residence. Subcutaneous administration is the standard administration route and the route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>ARA-290 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Diabetic neuropathy and small-fiber neuropathy studies<\/strong> \u2014 corneal nerve-fiber density assessment, intra-epidermal nerve-fiber density (IENFD), neuropathic-pain scoring; lead clinical studies indication, with Phase 2 trials in type 2 diabetic neuropathy showing improvement in nerve-fiber regeneration and pain scores<\/li>\n<li><strong>Neuropat\u00eda de fibras peque\u00f1as asociada a sarcoidosis<\/strong> \u2014 the indication for which ARA-290 holds US and EU orphan-drug designation; preclinical and Phase 2 studies in granulomatous inflammation models<\/li>\n<li><strong>Neuropathic pain studies<\/strong> \u2014 neuropat\u00eda perif\u00e9rica inducida por quimioterapia, neuropat\u00eda postquir\u00fargica, disecci\u00f3n mecanicista de las v\u00edas del dolor mediadas por IRR<\/li>\n<li><strong>Ischemia-reperfusion injury studies<\/strong> \u2014 modelos renales, card\u00edacos y cerebrales de isquemia-reperfusi\u00f3n; caracterizaci\u00f3n de efectos anti-apopt\u00f3ticos y antiinflamatorios<\/li>\n<li><strong>Inflammation and innate immunity studies<\/strong> \u2014 polarizaci\u00f3n de macr\u00f3fagos, ensayos de supresi\u00f3n de citoquinas, disecci\u00f3n de se\u00f1alizaci\u00f3n dependiente vs independiente de IRR<\/li>\n<li><strong>Type 2 diabetes metabolic support<\/strong> \u2014 control gluc\u00e9mico, preservaci\u00f3n de c\u00e9lulas beta, comparaci\u00f3n con mecanismos sensibilizadores a la insulina<\/li>\n<li><strong>Corneal wound-healing and ophthalmic studies<\/strong> \u2014 tasa de cierre de heridas epiteliales corneales, regeneraci\u00f3n de fibras nerviosas en la c\u00f3rnea (uno de los tejidos m\u00e1s densamente inervados y un indicador sensible para la reparaci\u00f3n impulsada por IRR)<\/li>\n<\/ul>\n<p>For broader context on related anti-inflammatory and tissue-repair peptides, see <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a> (reparaci\u00f3n tisular GI\/MSK derivada de p\u00e9ptidos g\u00e1stricos), <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a> (fragmento de Timosina Beta-4, reparaci\u00f3n tisular amplia), y <a href=\"https:\/\/medsbase.com\/es\/kpv-lysine-proline-valine\/\">KPV<\/a> (trip\u00e9ptido antiinflamatorio derivado de \u03b1-MSH). Explore el <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks ARA-290 in 10 mg lyophilized vials calibrated to typical protocol lengths. Available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 multi-week protocols across diabetic neuropathy, ischemia-reperfusion, corneal-repair, and inflammation models; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Clinical Phase 2 doses in published trials are 4 mg subcutaneous daily for diabetic neuropathy and sarcoidosis-associated neuropathy, so a single 10 mg pharmaceutical-grade vial represents a multi-day supply of clinical-equivalent dosing for in-vivo work. ARA-290 is supplied as the unmodified linear 11-mer \u2014 there is no acyl chain, no PEGylation, no disulfide bridge, and reconstitution is straightforward relative to longer or modified peptides. <\/p>\n<h2>C\u00f3mo se comparan \u2014 ARA-290 vs BPC-157<\/h2>\n<p>ARA-290 y <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a> are both used in tissue-repair and anti-inflammatory studies, but the two peptides target entirely different molecular machinery. ARA-290 is an EPO-derived innate-repair-receptor agonist that drives JAK2\/STAT3 cytoprotective signalling. BPC-157 is a 15-amino-acid synthetic stable gastric pentadecapeptide derived from a fragment of human gastric juice protein BPC, acting through a complex multi-pathway mechanism including nitric oxide synthase modulation, VEGF upregulation, and growth-factor-receptor cross-talk. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">ARA-290<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">BPC-157<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Origen<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">H\u00e9lice B de la eritropoyetina humana (HBSP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fragmento de la prote\u00edna BPC del jugo g\u00e1strico humano<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">11 amino\u00e1cidos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">15 amino\u00e1cidos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Receptor \/ diana<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Receptor innato de reparaci\u00f3n (EPOR + \u03b2cR \/ CD131)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">M\u00faltiples v\u00edas: sintasa de NO, VEGF, comunicaci\u00f3n cruzada con factores de crecimiento<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Primary studies tissue<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nervio perif\u00e9rico, c\u00f3rnea, tejido isqu\u00e9mico, tejido inflamado<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Tend\u00f3n, ligamento, mucosa intestinal, m\u00fasculo<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efecto eritropoy\u00e9tico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ninguno (caracter\u00edstica clave del dise\u00f1o)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">N\/A (no es un p\u00e9ptido de la v\u00eda EPO)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vida media plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2 minutos (el efecto persiste 24\u201372 horas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30 minutos (biodisponibilidad oral reportada en estudios precl\u00ednicos)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Desarrollo cl\u00ednico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fase 2 (neuropat\u00eda diab\u00e9tica, SFN por sarcoidosis); designaci\u00f3n de medicamento hu\u00e9rfano<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Solo precl\u00ednico (sin ensayos cl\u00ednicos con reguladores principales)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Modificaci\u00f3n<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">P\u00e9ptido lineal de 11 amino\u00e1cidos sin modificar<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">P\u00e9ptido lineal de 15 amino\u00e1cidos sin modificar (sal de acetato o arginato estable)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on neuropathic-pain, peripheral-nerve regeneration, or IRR-mediated cytoprotection, ARA-290 is the targeted reference peptide. For studies focused on musculoskeletal tendon\/ligament repair or gastrointestinal mucosal healing, <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a> remains the more widely-studied option. The two peptides are sometimes combined in protocols that aim to recruit complementary repair pathways across both CNS\/peripheral-nerve tissue and connective tissue. See also <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a> (fragmento de Timosina Beta-4, referencia amplia en reparaci\u00f3n tisular) y <a href=\"https:\/\/medsbase.com\/es\/kpv-lysine-proline-valine\/\">KPV<\/a> (trip\u00e9ptido antiinflamatorio derivado de \u03b1-MSH). <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 \u00bfNecesitas agua BAC?<\/strong> La reconstituci\u00f3n de cualquier vial liofilizado requiere agua bacteriost\u00e1tica est\u00e9ril. Combina este producto con nuestro <a href=\"\/es\/bac-water\/\"><strong>Agua BAC (Agua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 vial multidosis de 30 mL, conservado con alcohol benc\u00edlico 0.9%, grado USP.<\/div>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su envase original para existencias de uso a corto plazo. Para almacenamiento a largo plazo sin abrir, congele a \u221220 \u00b0C. El ARA-290 liofilizado es estable bajo refrigeraci\u00f3n hasta 24 meses y a \u221220 \u00b0C hasta 36 meses. Evite ciclos de congelaci\u00f3n-descongelaci\u00f3n en el polvo liofilizado. El ARA-290 es un p\u00e9ptido lineal no modificado sin puentes disulfuro ni cadenas acilo, por lo que su manipulaci\u00f3n es m\u00e1s sencilla en comparaci\u00f3n con p\u00e9ptidos estructuralmente complejos como el cagrilintida o el semaglutida. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 10 mg vial, 2.0 mL of bacteriostatic water yields a 5 mg\/mL working concentration \u2014 0.08 mL delivers 400 mcg (a 1 mg dose requires 0.2 mL); 0.8 mL delivers a clinical-equivalent 4 mg dose. Swirl gently \u2014 do not shake vigorously, as foaming entrains air and can denature peptide chains. Allow the powder to dissolve fully (typically &lt;1 minute for ARA-290) before withdrawing. Once reconstituted, store the vial at 2\u20138 \u00b0C and use within 14\u201328 days. Protect from light. Discard if cloudiness, particulates, or colour change appears. <\/p>\n<h2>Preguntas frecuentes<\/h2>\n<h3>\u00bfEs el ARA-290 un an\u00e1logo de la EPO? \u00bfAumenta el hematocrito?<\/h3>\n<p>El ARA-290 se deriva de la h\u00e9lice B de la eritropoyetina, pero est\u00e1 dise\u00f1ado espec\u00edficamente para <em>ajuste<\/em> aumentar el hematocrito. El efecto eritropoy\u00e9tico cl\u00e1sico de la EPO est\u00e1 mediado por el receptor homodim\u00e9rico de EPO (EPOR<sub>2<\/sub>) en progenitores eritroides de la m\u00e9dula \u00f3sea. El ARA-290 se une en cambio al receptor de reparaci\u00f3n innata heterom\u00e9rico (EPOR + \u03b2cR\/CD131), y tiene afinidad insignificante por el EPOR<sub>2<\/sub>. Los ensayos de Fase 2 publicados no muestran cambios en hemoglobina, hematocrito o recuento de reticulocitos tras dosis repetidas. <\/p>\n<h3>\u00bfQu\u00e9 es el receptor de reparaci\u00f3n innata (IRR)?<\/h3>\n<p>El receptor de reparaci\u00f3n innata es un heterocomplejo de la subunidad del receptor de EPO (EPOR) y el receptor beta com\u00fan (\u03b2cR, tambi\u00e9n conocido como CD131 \u2014 la subunidad de se\u00f1alizaci\u00f3n compartida por los receptores de GM-CSF, IL-3 e IL-5). El IRR se regula al alza localmente en tejidos estresados, lesionados o inflamados en lugar de expresarse constitutivamente, raz\u00f3n por la cual el ARA-290 act\u00faa como una se\u00f1al de reparaci\u00f3n tisular restringida al contexto en lugar de un agonista sist\u00e9mico. <\/p>\n<h3>\u00bfPor qu\u00e9 el ARA-290 tambi\u00e9n se llama cibinetida?<\/h3>\n<p>ARA-290 es el c\u00f3digo de desarrollo asignado por Araim Pharmaceuticals (el desarrollador original). Cibinetida es el nombre com\u00fan internacional (INN) asignado posteriormente para contextos de ensayos cl\u00ednicos y regulatorios. Ambos nombres se refieren al mismo p\u00e9ptido de 11 amino\u00e1cidos (CAS 1208243-50-8). <\/p>\n<h3>\u00bfPor qu\u00e9 la vida media plasm\u00e1tica es tan corta en relaci\u00f3n con la duraci\u00f3n del efecto?<\/h3>\n<p>ARA-290 tiene una vida media en plasma de aproximadamente 2 minutos \u2014 el p\u00e9ptido se elimina r\u00e1pidamente de la circulaci\u00f3n \u2014 pero el efecto biol\u00f3gico persiste durante 24\u201372 horas a trav\u00e9s de la activaci\u00f3n descendente de las cascadas de se\u00f1alizaci\u00f3n JAK2\/STAT3, PI3K\/Akt y anti-apopt\u00f3ticas de la familia Bcl-2. Este perfil farmacocin\u00e9tico es t\u00edpico de los p\u00e9ptidos activados por receptores, donde la duraci\u00f3n est\u00e1 determinada por la cin\u00e9tica de la cascada de se\u00f1alizaci\u00f3n en lugar de por niveles plasm\u00e1ticos sostenidos. <\/p>\n<h3>How does ARA-290 compare to BPC-157 for tissue repair studies?<\/h3>\n<p>Both peptides are used in tissue-repair studies but target different machinery and different tissues. ARA-290 acts via the innate repair receptor (EPOR + CD131) and is best-characterised in peripheral-nerve, corneal, and ischemic-tissue studies. <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a> acts through a multi-pathway mechanism involving nitric oxide synthase modulation and VEGF upregulation, and is best-characterised in tendon, ligament, gut mucosal, and muscle studies. Some protocols combine the two peptides to recruit complementary repair pathways. <\/p>\n<h3>\u00bfQu\u00e9 es la neuropat\u00eda de fibras peque\u00f1as asociada a sarcoidosis y por qu\u00e9 ARA-290 tiene designaci\u00f3n de medicamento hu\u00e9rfano para ella?<\/h3>\n<p>Sarcoidosis is a granulomatous inflammatory disease that produces a debilitating small-fiber neuropathy (SFN) in a substantial fraction of affected patients. ARA-290 holds US FDA and EU EMA orphan-drug designation for sarcoidosis-associated SFN, reflecting the rarity of the indication and the absence of other targeted treatments. The orphan designation supports clinical studies but does not constitute approval \u2014 ARA-290 is investigational at the time of this writing. <\/p>\n<h3>What is the standard dose for ARA-290?<\/h3>\n<p>Published Phase 2 clinical trials have used 2\u20134 mg subcutaneous daily for diabetic neuropathy and sarcoidosis-associated SFN. Preclinical animal studies have used wider dose ranges depending on model and tissue. Users should determine dose ranges from peer-reviewed literature appropriate to their specific protocol. <\/p>\n<h3>\u00bfRequiere ARA-290 un manejo especial debido a las modificaciones de disulfuro o acilo?<\/h3>\n<p>No. ARA-290 es un p\u00e9ptido lineal de 11 amino\u00e1cidos sin modificar, sin puente de disulfuro, sin acilaci\u00f3n de \u00e1cidos grasos y sin PEGilaci\u00f3n. La reconstituci\u00f3n y el manejo son sencillos \u2014 un suave agitado disuelve el polvo liofilizado en ~1 minuto. Compare esto con p\u00e9ptidos estructuralmente complejos como cagrilintida (cadena acilo + disulfuro), semaglutida (cadena acilo) o p\u00e9ptidos de la clase de la insulina, donde la reconstituci\u00f3n requiere un tiempo de equilibraci\u00f3n m\u00e1s largo. <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 P\u00e9ptido de 11 amino\u00e1cidos derivado de EPO no eritropoy\u00e9tico<br \/>\n\u2705 Agonista del receptor de reparaci\u00f3n innata (EPOR + CD131)<br \/>\n\u2705 Se\u00f1alizaci\u00f3n antiinflamatoria, neuroprotectora y de reparaci\u00f3n tisular<br \/>\n\u2705 Sin elevaci\u00f3n del hematocrito (caracter\u00edstica clave frente a la EPO completa)<br \/>\n\u2705 Designado como medicamento hu\u00e9rfano para la neuropat\u00eda de fibras peque\u00f1as asociada a sarcoidosis<\/p>\n<p><strong>ARA-290<\/strong> contiene compuesto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":71396,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6461,6462,5441],"class_list":["post-71388","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-ara-290","product_tag-cibinetide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/71388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=71388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/71396"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=71388"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=71388"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=71388"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=71388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}